Zim Laboratories Ltd

- The transcript does not explicitly mention any current or future fundraising plans through debt or equity. - Borrowings for H1 FY24 stand at Rs. 601 million with a leverage ratio of 27%, and finance costs have declined by 30% quarter-on-quarter. - There is no indication from management about plans to raise additional funds via debt or equity in the near term. - Focus appears to be on improving operational performance and continuing growth through internal cash flow. - Management emphasizes ongoing investments in parts, machinery, and R&D but did not mention new fundraising to support these activities.

- ZIM Laboratories added Rs. 339 million to their gross block in H1 Financial Year ’24 for parts and machinery upgrades. - The company continues committing to ongoing parts and machinery upgradation to support growth. - No specific future capital expenditure or strategic investment numbers were disclosed during the call. - Management emphasized ongoing efforts towards research and development with R&D investment at 9.4% of total operating income in Q2 FY24. - Focus on investment seems to be on plant and machinery enhancement and technology upgrades to support product development and filings in regulated markets.

- The company expects significant traction and positive growth in New Innovative Products (NIP) and oral thin film (OTF) products, especially in regulated markets starting from the second half of FY25. - Several filings and registrations are underway in regulated and emerging markets, with approvals anticipated by the end of FY24 and volume growth expected thereafter. - Current order books are robust, with the company aiming to maintain or exceed FY24 revenue performance. - The revenue contribution from NIP and OTF is increasing, currently at 13% of total revenue, with a positive trend expected in upcoming quarters. - Margins are likely to improve alongside revenue growth, supported by operating leverage and product mix enhancement. - The company remains cautious about specifying exact figures due to market dynamics but is confident about achieving the projected growth trajectory by FY25.

- FY25 is expected to see the initial positive impact of efforts in New Innovative Products (NIP) and regulated markets, with growth starting to become visible after 6-8 quarters. - The management remains confident that FY25 numbers will align with previously projected strategic growth despite market dynamics. - Revenue from NIP and oral products in regulated and emerging markets is expected to gain traction, positively impacting overall revenue and margins over time. - For FY24, the company expects to maintain performance levels similar to the previous year with a robust order book. - Margins are anticipated to improve sequentially, aided by operating leverage as volumes increase. - R&D expenses will remain around 7-8% of overall revenue, supporting continued innovation. - The regulated market segment contribution will increase notably by the second half of FY25, driving growth and margin enhancement. Overall, ZIM Laboratories aims for steady revenue growth with improving margins driven by new product launches and market expansion through FY24 and FY25.

- The current order position for FY24 is robust, showing steady growth and recovery from earlier external challenges (Page 6). - Orders in Nutraceuticals, India, Asia, and Southeast Asia indicate derisking and steady increase in demand (Page 8). - The company expects further traction and positive trends in NIP and OTF product sales within regulated and emerging markets over the coming quarters (Pages 11-12). - Several agreements are being signed currently, though exact numbers are not shared due to market dynamics and timelines (Page 11). - The order book and ongoing efforts suggest stability for FY24, with confidence in maintaining performance levels similar to the previous year (Pages 6 and 11). - The impact of pending Marketing Authorizations and product launches is expected to start reflecting significantly only from the second half of FY25 (Pages 8-9, 12).